Novel mAb Contraceptive + Tenofovir Disoproxil Fumarate Intravaginal Ring
Novel mAb Contraceptive + TDF IVR
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal Ring
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Oak Crest Institute of Science, University of North Carolina
Details
- API: Multivalent Monoclonal Antibody, Tenofovir Disoproxil Fumarate
-
Mechanism of Action:
- Inhibition of Sperm Motility
- Anti-Microbial
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Potential MPT
- Promising Attributes: The method offers both pregnancy prevention and HIV prevention. It is non-hormonal, using a novel anti-body against sperm, and could potentially cause fewer side-effects.
Product Status
Active Pre-Clinical Research
History
An NIH grant was awarded in 2021 to develop a novel antibody against sperm and formulate this agent into an intravaginal ring for extended delivery, along with drugs effective against HIV.